Abstract
This study aimed to characterize the prevalence of screening positive for attention-deficit/hyperactivity disorder (ADHD) among patients seeking methadone treatment for opioid use disorder (OUD) at an opioid treatment program (OTP) to study the association between screening positivity and patient retention. Data from 66 individuals were included in the analysis. Using the ASRS-5 screening tool, 30 (45.5%) screened positive for ADHD at intake. Of the individuals who screened positive for ADHD, 16 (53.3%) left care within 2 months of starting the opioid treatment program compared to the 15 (41.7%) who screened negative, suggesting no significant difference in retention between the two groups. This study’s results indicate individuals with OUD may have a higher prevalence of ADHD compared to the general population, underscoring the need for effective strategies to care for high-risk dual diagnosis patients.
Keywords
Attention-deficit/hyperactivity disorder, Opioid use disorder, Methadone